1. Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents
- Author
-
Erika Yamamoto, Cabg Registry Cohort, Ko Yamamoto, Naritatsu Saito, Takeshi Kimura, cohort investigators, Kenji Ando, Satoru Suwa, Takeshi Tada, Yusuke Yoshikawa, Kazushige Kadota, Mph Eri T. Kato, Hirotoshi Watanabe, Yasuaki Takeji, Ryuzo Nawada, Toshihiro Tamura, Yutaka Furukawa, Katsuhisa Ishii, Yoshihisa Nakagawa, Tomoya Onodera, Takenori Domei, Yukiko Matsumura-Nakano, CREDO-Kyoto Pci, Hiroki Shiomi, and Mph Takeshi Morimoto
- Subjects
stent thrombosis ,Drug ,medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,medicine.medical_treatment ,Stent ,Percutaneous coronary intervention ,Lower risk ,dual antiplatelet therapy ,medicine.anatomical_structure ,Drug-eluting stent ,Internal medicine ,Conventional PCI ,drug-eluting stent ,medicine ,Cardiology ,cardiovascular diseases ,business ,Adverse effect ,Artery ,media_common - Abstract
[Background] There are limited data on the long-term stent-related adverse events as related to the duration of dual antiplatelet therapy (DAPT) in second-generation (G2) drug-eluting stents (DES) compared with first-generation (G1) DES. [Objectives] This study sought to compare the long-term stent-related outcomes of G2-DES with those of G1-DES. [Methods] The study group consisted of 15, 009 patients who underwent their first coronary revascularization with DES from the CREDO-Kyoto PCI/CABG (Coronary Revascularization Demonstrating Outcome Study in Kyoto Percutaneous Coronary Intervention/Coronary Artery Bypass Grafting) Registry Cohort-2 (first-generation drug-eluting stent [G1-DES] period; n = 5, 382) and Cohort-3 (second-generation drug eluting stent [G2-DES] period; n = 9, 627). The primary outcome measures were definite stent thrombosis (ST) and target vessel revascularization (TVR). [Results] The cumulative 5-year incidences of definite ST and TVR were significantly lower in the G2-DES group than in the G1-DES group (0.7% vs 1.4%; P < 0.001; and 16.2% vs 22.1%; P < 0.001, respectively). The lower adjusted risk of G2-DES relative to G1-DES for definite ST and TVR remained significant (HR: 0.53; 95% CI: 0.37-0.76; P < 0.001; and HR: 0.74; 95% CI: 0.68-0.81; P < 0.001, respectively). In the landmark analysis that was based on the DAPT status at 1 year, the lower adjusted risk of on-DAPT status relative to off-DAPT was significant for definite ST beyond 1 year in the G1-DES stratum (HR: 0.42; 95% CI: 0.24-0.76; P = 0.004) but not in the G2-DES stratum (HR: 0.66; 95% CI: 0.26-1.68; P = 0.38) (Pinteraction = 0.14). [Conclusions] G2-DES compared with G1-DES were associated with a significantly lower risk for stent-related adverse events, including definite ST and TVR. DAPT beyond 1 year was associated with a significantly lower risk for very late ST of G1-DES but not for that of G2-DES.
- Published
- 2021